🔗 Share this article

The initial novel therapies for gonorrhoea in a generation are being viewed as a "huge turning point" in the fight against increasingly resistant strains of the infection, according to scientists.

A Global Public Health Issue

Gonorrhoea infections are escalating globally, with data suggesting over 82 million infections each year. Particularly high rates are reported in Africa and countries within the WHO's Western Pacific region, which includes China and Mongolia to New Zealand. Within England, cases have reached a historical peak, while figures across Europe in 2023 were triple the level compared to those in 2014.

“The clearance of novel therapies for gonorrhoea is an important and timely step in the reality of increasing worldwide cases, the spread of superbugs and the extremely scarce available drugs presently on offer.”

Medical experts are particularly alarmed about the increase in drug-resistant strains. The WHO has classified it as a "critical concern". Recent surveillance found that resistance to standard treatments like ceftriaxone and cefixime increased dramatically between 2022 and 2024.

Two New Drugs Secure Clearance

Zoliflodacin, marketed under the name a brand name, was cleared by the US Food and Drug Administration in December for treating gonorrhoea. This infection can lead to significant complications, including infertility. Researchers hope that focused deployment of this new drug will help delay the emergence of superbugs.

Another new antibiotic, developed by the drugmaker GlaxoSmithKline, also received approval in concurrent days. This drug, which is employed against urinary tract infections, was shown in trials to be effective against antibiotic-resistant forms of the gonorrhoea bacteria.

A Unique Partnership

This new treatment stemmed from a innovative non-profit model for drug creation. The charitable organization Global Antibiotic Research & Development Partnership partnered with the pharmaceutical company Innoviva to see it through.

“This authorization signifies a significant shift in the therapy of multidrug-resistant gonorrhoea, which up to this point has been evolving faster than our drug pipeline.”

Testing Results and Global Access

As per findings released by a prominent scientific publication, zoliflodacin eradicated more than 90% of cases of the STI. This establishes an comparable level with the current standard treatment, which involves an injection and a pill. The research included nearly 1,000 volunteers from several countries including Belgium, the Netherlands, South Africa, Thailand and the US.

As part of the agreement of its development partnership, GARDP has the authority to license and sell the drug in numerous low-income and middle-income countries.

Medical professionals directly involved have expressed hope. The availability of a one-pill regimen like this is hailed as a "critical tool" for gonorrhoea control. This is viewed as essential to alleviate the strain of the disease for individuals and to prevent the spread of extremely resistant gonorrhoea globally.